Loading...
•
Sep 30, 2021
Atricure Q3 2021 Earnings Report
Reported a revenue increase of 28.7% and income from operations of $98.7 million.
Key Takeaways
AtriCure reported strong third-quarter results, driven by growth across key product lines and the addition of new Cryo Nerve Block and Hybrid AF™ Therapy accounts. Revenue increased by 28.7% year-over-year, with U.S. and international revenue showing healthy growth. The company is maintaining its full-year revenue guidance.
Revenue for the third quarter 2021 was $70.5 million, an increase of 28.7% over third quarter 2020 revenue.
U.S. revenue was $57.5 million, an increase of 28.7% compared to third quarter 2020 revenue.
International revenue increased 28.5% to $12.9 million.
Basic and diluted net income per share was $2.15 and $2.11, respectively, for the third quarter 2021.
Revenue by Geographic Location
Forward Guidance
Management is maintaining revenue guidance for full year 2021 at a range of $270 to $275 million, corresponding to growth of approximately 31% to 33% for the year. The Company is also maintaining guidance for full year 2021 adjusted EBITDA loss of approximately $10 million and an adjusted loss per share of approximately $1.20.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...